Navigation Links
Electrophysiology Procedures for Atrial Fibrillation Treatment to Grow Over 25% Annually Over the Next Five Years
Date:3/20/2008

Growth will be driven by an increasing physician acceptance of

electrophysiology ablation as an effective treatment for atrial

fibrillation, according to Millennium Research Group

WALTHAM, Mass., March 20 /PRNewswire/ -- According to Millennium Research Group's Global Markets for Atrial Fibrillation (AF) Treatment Devices 2008 report, over 32,000 electrophysiology (EP) procedures were performed for the treatment of AF in the US in 2007. AF EP procedure volumes will increase at a compound annual growth rate of over 25% from 2008 to 2012.

Growth in procedure volumes will be driven by the increasing physician acceptance of EP ablation as a viable and effective treatment for AF. Over the next several years, these procedures will be used more often over medical therapy than in the past. The introduction of new technology will also support greater procedure volumes through 2012; these new devices will enable physicians to increase the safety, efficiency, and efficacy of EP ablation catheter procedures. By 2012, over 109,000 EP procedures will be performed to treat AF in the US.

"The patient pool that hasn't been treated in this market is huge and growing," says Andrew Wong, Analyst at Millennium Research Group. "Almost 3 million people have atrial fibrillation in the US, but currently only about 100,000 are being treated annually."

The Global Markets for Atrial Fibrillation Treatment Devices 2008 report includes coverage of the AF EP, cardiac rhythm management, and surgical ablation device markets. This report provides coverage of US, Europe, and Japan and all key industry competitors, including Biosense Webster, Boston Scientific, Medtronic, and St. Jude Medical.

About Atrial Fibrillation

AF is a type of cardiac arrhythmia. In AF, the atria of the heart are stimulated by abnormal electrical impulses from the sinoatrial node and malfunctioning atrial tissue, resulting in an irregular and disorganized heart beat. AF can lead to heart failure and has been recognized as a major risk factor for stroke. Increased age and unhealthy lifestyle choices are risk factors in developing AF.

About Millennium Research Group

Millennium Research Group (http://www.MRG.net), a Decision Resources, Inc. company (http://www.DecisionResources.com), is the global authority on medical technology market intelligence and a leading provider of strategic information to the health care sector. Focused solely on the medical device, pharmaceutical, and biotechnology industries, the company provides its clients with the benefits of its specialized industry expertise through published reports and customized consulting services.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Amy Krohn

Millennium Research Group

416-364-7776 x101

akrohn@mrg.net


'/>"/>
SOURCE Millennium Research Group
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Signalife Presence at XIII World Congress on Cardiac Pacing and Electrophysiology
2. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
3. Stereotaxis Niobe System Used to Perform More Than 10,000 Procedures Worldwide
4. Hyaluronic Acid Knee Procedures Grow 38% from Q3 2006 to Q3 2007
5. Anesiva Announces Submission of Supplemental New Drug Application for Zingo(TM) to Reduce Pain Associated With Needle Insertion Procedures in Adults
6. CryoCor to Highlight Products at 13th Annual International Boston Atrial Fibrillation Symposium
7. AtriCure Announces Initiation of the ABLATE Pivotal Trial to Evaluate the Isolator Synergy(TM) Bipolar Ablation System to Treat Atrial Fibrillation
8. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
9. Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup
10. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
11. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , ... April 20, 2017 , ... ... the scientific and clinical research community’s growing body of knowledge during its ... the Gracie Theatre and the adjacent Darling Atrium. During the event, undergraduates, graduate ...
(Date:4/20/2017)... LAVAL, QC , April 20, 2017 /PRNewswire/ - Prometic Life ... today presented new results at the International Liver Congress ("ILC") ... Liver ("EASL") in Amsterdam on the ... in a mouse model of obesity and metabolic syndrome. ... According to Dr. Lyne Gagnon, ...
(Date:4/20/2017)... CA (PRWEB) , ... April 20, 2017 , ... ... of clinical trials worldwide, announced today that they were named one of the ... which covers the latest developments in the pharmaceutical industry. , “We take pride in ...
(Date:4/20/2017)... April 20, 2017 Dutch philosopher Koert van Mensvoort - ... at the University of Technology in Eindhoven - has written a ,Letter ... he calls on humanity to avoid becoming a slave and victim to its ... ... Dutch philosopher Koert van Mensvoort – founder of the Next Nature ...
Breaking Biology Technology:
(Date:3/30/2017)... -- The research team of The Hong Kong Polytechnic ... by adopting ground breaking 3D fingerprint minutiae recovery and matching technology, ... accuracy for use in identification, crime investigation, immigration control, security of ... ... A research team led by Dr ...
(Date:3/29/2017)... , March 29, 2017  higi, the health IT ... North America , today announced a ... the acquisition of EveryMove. The new investment and acquisition ... of tools to transform population health activities through the ... data. higi collects and secures data today ...
(Date:3/27/2017)... March 27, 2017  Catholic Health Services (CHS) ... Systems Society (HIMSS) Analytics for achieving Stage 6 ... sm . In addition, CHS previously earned a ... using an electronic medical record (EMR). ... level of EMR usage in an outpatient setting.  ...
Breaking Biology News(10 mins):